# A Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma

> **NCT00512863** · PHASE2 · WITHDRAWN · sponsor: **Abbott** · enrollment: 272 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Humira (adalimumab)

## Key facts

- **NCT ID:** NCT00512863
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 272 (ESTIMATED)
- **Last updated:** 2007-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00512863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00512863, "A Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00512863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*